Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astellas Pharma Will Buy Agensys

December 3, 2007 | A version of this story appeared in Volume 85, Issue 49

Japan's Astellas Pharma will pay $387 million upfront to acquire Agensys of Santa Monica, Calif. Agensys' shareholders could also receive up to $150 million if certain business milestones are met. Ten-year-old Agensys focuses on therapeutic antibody R&D in the area of cancer. It has 30 targets identified in 14 cancer types, technology to generate fully human monoclonal antibodies, and production facilities that can supply preclinical and early clinical studies. Astellas plans to make the business a cornerstone of its oncology business and its expanding biologics efforts.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.